The combination of venetoclax, daratumumab and dexamethasone for the treatment of refractory primary plasma cell leukemia

A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis

(2018) Brian A. Walker et al.   LEUKEMIA

Targeting Bcl-2 for the treatment of multiple myeloma

(2018) Cyrille Touzeau et al.   LEUKEMIA

Single-agent venetoclax induces MRD-negative response in relapsed primary plasma cell leukemia with t(11;14)

(2018) Tomas Jelinek et al.   AMERICAN JOURNAL OF HEMATOLOGY

Combination therapy incorporating Bcl-2 inhibition with Venetoclax for the treatment of refractory primary plasma cell leukemia with t (11;14)

(2017) Wilson I. Gonsalves et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

(2017) Carolina Schinke et al.   HAEMATOLOGICA

The prognostic value of the depth of response in multiple myeloma depends on the time of assessment, risk status and molecular subtype

(2017) Carolina Schinke et al.   HAEMATOLOGICA

Primary plasma cell leukemia: clinical and laboratory presentation, gene-expression profiling and clinical outcome with Total Therapy protocols

(2012) S Z Usmani et al.   LEUKEMIA